Beyond the ITC white paper: Emerging sciences in drug transporters and opportunities for drug development

Current Pharmaceutical Design

Volumn 20, Issue 10, 2014, Pages 1577-1594

  Lai, Yurong ^a,b   Hsiao, Peng ^c  

^a PFIZER INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug induced organ toxicity; Drug transporters; Drug drug interaction; Gene polymorphism; Intracellular concentration; Organ targeting; Tissue specific exposure

Indexed keywords

ABC TRANSPORTER; AMINO ACID TRANSPORTER; BILE SALT EXPORT PUMP; CEFALORIDINE; CISPLATIN; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 9; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 3; NEUROTRANSMITTER TRANSPORTER; ORGANIC ANION TRANSPORTER B; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PH DEPENDENT PROTON COUPLE AMINO ACID TRANSPORTER; PROTON COUPLED FOLATE TRANSPORTER; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; SODIUM GLUCOSE COTRANSPORTER 2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TROGLITAZONE; UNCLASSIFIED DRUG; URATE TRANSPORTER; URATE TRANSPORTER 1; ZINC TRANSPORTER; ZINC TRANSPORTER 8;

CELL SURVIVAL; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DRUG INTERACTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG INTERACTION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOXICITY; DRUG TRANSPORT; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER INJURY; MUSCLE INJURY; NEPHROTOXICITY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TARGET ORGAN; TRANSPORT KINETICS;

BIOLOGICAL TRANSPORT; COOPERATIVE BEHAVIOR; DRUG DESIGN; DRUG DISCOVERY; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTERNATIONALITY; MEMBRANE TRANSPORT PROTEINS;

EID: 84897441042     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990467     Document Type: Review

References (178)

1. Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008; 18: 4872-5.
2. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-49.
3. Benet LZ, Broccatelli F, Oprea TI. BDDCS Applied to Over 900 Drugs. AAPS J 2011; 13(4): 519-47.
4. Varma MV, Ambler CM, Ullah M, et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010; 11: 730-42.
5. Kusuhara H, Sugiyama Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 2009; 24: 37-52.
6. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 2006; 6: 494-500.
7. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2: 3-14.
8. Terasaki T, Pardridge WM. Targeted drug delivery to the brain; (blood-brain barrier, efflux, endothelium, biological transport). J Drug Target 2000; 8: 353-5.
9. Fexofenadine http://www. accessdata. fda. gov/drugsatfda_docs/label/2003/20786se8-014, 20872se8-011, 20625se8-012_allegra_lbl. pdf 2003.
10. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298-304.
11. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-36.
12. The_EMA_guidancehttp://www. emea. europa. eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112. pdf 2012.
13. The_FDA_guidance http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm29236 2. pdf 2012.
14. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-31.
15. Ahlin G, Chen L, Lazorova L, et al. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 2011; 11: 400-11.
16. Dickens D, Owen A, Alfirevic A, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol 2012; 83: 805-14.
17. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24: 1803-23.
18. Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM. Highlights from the international transporter consortium second workshop. Clin Pharmacol Ther 2012; 92: 553-6.
19. Castellino S, O'Mara M, Koch K, Borts DJ, Bowers GD, MacLauchlin C. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 2012; 40: 139-50.
20. Ito S, Kusuhara H, Yokochi M, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2012; 340: 393-403.
21. Matsushima S, Maeda K, Inoue K, et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 2009; 37: 555-9.
22. Ito S, Kusuhara H, Kuroiwa Y, et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010; 333: 341-50.
23. Bhutta TI, Tahir KI. Loperamide poisoning in children. Lancet 1990; 335: 363.
24. McCowat LA, Cutting WA, Steinke D, MacDonald TM. Treating diarrhoea. Children deserve special attention. Bmj 1997; 315: 1378-9; author reply 1379-80.
25. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231-7.
26. Hsiao P, Unadkat JD. P-glycoprotein-based loperamidecyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans. Mol Pharm 2012; 9: 629-33.
27. Chintagumpala MM, Friedman HS, Stewart CF, et al. A phase II window trial of procarbazine and topotecan in children with highgrade glioma: a report from the children's oncology group. J Neurooncol 2006; 77: 193-8.
28. Carcaboso AM, Elmeliegy MA, Shen J, et al. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 2010; 70: 4499-508.
29. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-5.
30. Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 2012; 17: 419-24.
31. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 2011; 10: 328-9.
32. Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011; 10: 87.
33. Kannan S, Saadani-Makki F, Balakrishnan B, et al. Decreased cortical serotonin in neonatal rabbits exposed to endotoxin in utero. J Cereb Blood Flow Metab 2011; 31: 738-49.
34. Pfefferkorn JA, Litchfield J, Hutchings R, et al. Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution. Bioorg Med Chem Lett 2011; 21: 2725-31.
35. Nishimura M, Suzuki S, Satoh T, Naito S. Tissue-specific mRNA expression profiles of human solute carrier 35 transporters. Drug Metab Pharmacokinet 2009; 24: 91-9.
36. Nishimura M, Yoshitsugu H, Yokoi T, et al. Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 2005; 35: 877-90.
37. UCSF-FDA-TransPortal. http://bts. ucsf. edu/fdatransportal/index/.
38. Schaefer O, Ohtsuki S, Kawakami H, et al. Absolute Quantitation and Differential Expression of Drug Transporters, Cytochrome P450 Enzymes and UDP-Glucuronosyltransferases in Cultured Primary Human Hepatocytes. Drug Metab Dispos 2012; 40: 93-103.
39. Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-{alpha}, IL-6, and IL-1{beta}. J Biol Chem 2010; 285: 31185-92.
40. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
41. Cheung CH, Lin WH, Hsu JT, et al. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells. PLoS One 2011; 6: e23485.
42. Cheung CH, Coumar MS, Chang JY, Hsieh HP. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011; 21: 857-84.
43. Gether U, Andersen PH, Larsson OM, Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 2006; 27: 375-83.
44. Taniguchi A, Urano W, Yamanaka M, et al. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Arthritis Rheum 2005; 52: 2576-7.
45. Shin HJ, Takeda M, Enomoto A, et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrology (Carlton) 2011; 16: 156-62.
46. Nindita Y, Hamada T, Bahrudin U, et al. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA. Arzneimittelforschung 2010; 60: 186-8.
47. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15: 164-73.
48. Nakanishi T, Tamai I. Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. J Pharm Sci 2011; 100: 3731-50.
49. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005; 15: 254-66.
50. McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther 1995; 66: 465-505.
51. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652-62.
52. Lai Y, Varma M, Feng B, et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability-considerations for drug development. Expert Opin Drug Metab Toxicol 2012; 8: 723-43.
53. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302: 510-5.
54. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic aniontransporting polypeptides. J Pharmacol Exp Ther 2001; 298: 110-5.
55. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009; 58: 1434-9.
56. White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. Leukemia 2010; 24: 1962-5.
57. White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28: 2761-7.
58. Engler JR, Hughes TP, White DL. OCT-1 as a determinant of response to antileukemic treatment. Clin Pharmacol Ther 2011; 89: 608-11.
59. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227-51.
60. Somogyi A, Bochner F. Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man. Br J Clin Pharmacol 1984; 18: 175-81.
61. Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008; 84: 559-62.
62. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18: 637-45.
63. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299-306.
64. Christensen MM, Brasch-Andersen C, Green H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011; 21: 837-50.
65. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402.
66. Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmoller J, Benohr P. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 2011; 12: 1417-27.
67. Diao L, Shu Y, Polli JE. Uptake of pramipexole by human organic cation transporters. Mol Pharm 2010; 7: 1342-7.
68. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 2011; 12: 79-82.
69. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-81.
70. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001; 276: 35669-75.
71. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008; 66: 818-25.
72. Tachibana-Iimori R, Tabara Y, Kusuhara H, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19: 375-80.
73. Rodrigues AC, Perin PM, Purim SG, et al. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c. 388A>G Variant Is Determinant of Increased Atorvastatin Response. Int J Mol Sci 2011; 12: 5815-27.
74. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005; 280: 9610-7.
75. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATPB (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302: 804-13.
76. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19: 129-38.
77. Mougey EB, Lang JE, Wen X, Lima JJ. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol 2011; 51: 751-60.
78. Aoki M, Terada T, Ogasawara K, et al. Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenet Genomics 2009; 19: 647-56.
79. Adachi H, Suzuki T, Abe M, et al. Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol 2003; 285: F1188-97.
80. Huber RD, Gao B, Sidler Pfandler MA, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 2007; 292: C795-806.
81. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251-60.
82. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 2002; 16: 2283-96.
83. Gao B, Huber RD, Wenzel A, et al. Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. Exp Eye Res 2005; 80: 61-72.
84. Franke RM, Gardner ER, Sparreboom A. Pharmacogenetics of Drug Transporters. Curr Pharm Des 2010; 6: 220-230.
85. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005; 102: 17923-8.
86. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study. Diabetes 2009; 58: 745-749.
87. Toyama K, Yonezawa A, Tsuda M, et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenetics and Genomics 2010; 20: 135-138 10. 1097/FPC. 0b013e328335639f.
88. Choi JH, Yee SW, Ramirez AH, et al. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther 2011; 90: 674-84.
89. Carlton VE, Pawlikowska L, Bull LN. Molecular basis of intrahepatic cholestasis. Ann Med 2004; 36: 606-17.
90. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17: 47-60.
91. Ho RH, Leake BF, Kilkenny DM, et al. Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 2010; 20: 45-57.
92. Niemi M, Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistanceassociated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 2006; 16: 801-8.
93. Kivistö K, Niemi M. Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans. Pharmaceutical Research 2007; 24: 239-247.
94. Adachi M, Reid G, Schuetz JD. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev 2002; 54: 1333-42.
95. Krishnamurthy P, Schwab M, Takenaka K, et al. Transportermediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008; 68: 4983-9.
96. Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 2010; 45: 1014-21.
97. Aw W, Lezhava A, Hayashizaki Y, Ishikawa T. A new trend in personalized medicine: rapid detection of SNPs in drug transporter genes by the SmartAmp method. Clin Pharmacol Ther 2011; 89: 617-20.
98. Kool M, van der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999; 96: 6914-9.
99. Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF. Multidrug resistance-associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 2010; 37: 115-20.
100. Ansari M, Sauty G, Labuda M, et al. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics J 2012; 12: 386-94.
101. Lang T, Hitzl M, Burk O, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004; 14: 155-64.
102. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9: 545-59.
103. Kohler JJ, Hosseini SH. Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment. Methods Mol Biol 2011; 755: 267-77.
104. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest 2011; 91: 852-8.
105. Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Adv Exp Med Biol 1996; 394: 105-15.
106. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995; 39: 1247-52.
107. Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171: 788-96.
108. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11: 383-93.
109. Tune BM, Fravert D. Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin. Kidney Int 1980; 18: 591-600.
110. Group SC, Link E, Parish S, et al. SLCO1B1 variants and statininduced myopathy--a genomewide study. N Engl J Med 2008; 359: 789-99.
111. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 2006; 62: 409-15.
112. Funk C, Pantze M, Jehle L, et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 2001; 167: 83-98.
113. Gerloff T, Stieger B, Hagenbuch B, et al. The sister of Pglycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998; 273: 10046-50.
114. Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010; 118: 485-500.
115. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 2010; 80: 1762-7.
116. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74: 477-87.
117. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 6591-5.
118. Christ-Roberts CY, Pratipanawatr T, Pratipanawatr W, et al. Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 2004; 53: 1233-42.
119. Evason K, Bove KE, Finegold MJ, et al. Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies. Am J Surg Pathol 2011; 35: 687-96.
120. Chen ST, Chen HL, Su YN, et al. Prenatal diagnosis of progressive familial intrahepatic cholestasis type 2. J Gastroenterol Hepatol 2008; 23: 1390-3.
121. Wang L, Soroka CJ, Boyer JL. The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. J Clin Invest 2002; 110: 965-72.
122. van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004; 127: 379-84.
123. Keitel V, Vogt C, Haussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 2006; 131: 624-9.
124. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353: 210-1.
125. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis 2001; 21: 551-62.
126. Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120: 1448-58.
127. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 120: 1459-67.
128. Rosmorduc O, Hermelin B, Boelle PY, Parc R, Taboury J, Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003; 125: 452-9.
129. Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance pglycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102.
130. Ziol M, Barbu V, Rosmorduc O, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008; 135: 131-41.
131. Gong Z, Muzumdar RH. Pancreatic function, type 2 diabetes, and metabolism in aging. Int J Endocrinol 2012; 2012: 320482.
132. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001; 409: 729-33.
133. Elmendorf JS, Pessin JE. Insulin signaling regulating the trafficking and plasma membrane fusion of GLUT4-containing intracellular vesicles. Exp Cell Res 1999; 253: 55-62.
134. Pessin JE, Thurmond DC, Elmendorf JS, Coker KJ, Okada S. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location! J Biol Chem 1999; 274: 2593-6.
135. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998; 49: 235-61.
136. Graessler J, Graessler A, Unger S, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-8.
137. Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 2008; 27: 578-84.
138. Dehghan A, Yang Q, Peters A, et al. Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet 2009; 2: 125-33.
139. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504.
140. Vitart V, Rudan I, Hayward C, et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-42.
141. Wells RG, Mohandas TK, Hediger MA. Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics 1993; 17: 787-9.
142. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111: 544-7.
143. Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006; 69: 852-5.
144. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, Stromgaard K, Gether U. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 2011; 63: 585-640.
145. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 2003; 23: 4470-8.
146. Jonassen R, Endestad T, Neumeister A, Foss Haug KB, Berg JP, Landro NI. The effects of the serotonin transporter polymorphism and age on frontal white matter integrity in healthy adult women. Front Hum Neurosci 2012; 6: 19.
147. Jonassen R, Endestad T, Neumeister A, Foss Haug KB, Berg JP, Landro NI. Serotonin transporter polymorphism modulates N-back task performance and fMRI BOLD signal intensity in healthy women. PLoS One 2012; 7: e30564.
148. Drabant EM, Ramel W, Edge MD, et al. Neural mechanisms underlying 5-HTTLPR-related sensitivity to acute stress. Am J Psychiatry 2012; 169: 397-405.
149. Morey RA, Hariri AR, Gold AL, et al. Serotonin transporter gene polymorphisms and brain function during emotional distraction from cognitive processing in posttraumatic stress disorder. BMC Psychiatry 2011; 11: 76.
150. Suviolahti E, Oksanen LJ, Ohman M, et al. The SLC6A14 gene shows evidence of association with obesity. J Clin Invest 2003; 112: 1762-72.
151. Durand E, Boutin P, Meyre D, et al. Polymorphisms in the amino acid transporter solute carrier family 6 (neurotransmitter transporter) member 14 gene contribute to polygenic obesity in French Caucasians. Diabetes 2004; 53: 2483-6.
152. Meyre D, Lecoeur C, Delplanque J, et al. A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22. 31-q23. 2. Diabetes 2004; 53: 803-11.
153. Westergaard H. Bile Acid malabsorption. Curr Treat Options Gastroenterol 2007; 10: 28-33.
154. Pattni S, Walters JR. Recent advances in the understanding of bile acid malabsorption. Br Med Bull 2009; 92: 79-93.
155. Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99: 1880-7.
156. Sperling O. Renal hypouricemia: classification, tubular defect and clinical consequences. Contrib Nephrol 1992; 100: 1-14.
157. Jang WC, Nam YH, Ahn YC, et al. G109T polymorphism of SLC22A12 gene is associated with serum uric acid level, but not with metabolic syndrome. Rheumatol Int 2012; 32: 2257-63.
158. Sperling O. Hereditary renal hypouricemia. Mol Genet Metab 2006; 89: 14-8.
159. Komatsuda A, Iwamoto K, Wakui H, Sawada K, Yamaguchi A. Analysis of mutations in the urate transporter 1 (URAT1) gene of Japanese patients with hypouricemia in northern Japan and review of the literature. Ren Fail 2006; 28: 223-7.
160. Chimienti F, Favier A, Seve M. ZnT-8, a pancreatic beta-cellspecific zinc transporter. Biometals 2005; 18: 313-7.
161. Kaser H, Cottier P, Antener I. Glucoglycinuria, a new familial syndrome. J Pediatr 1962; 61: 386-94.
162. Broer S. Apical transporters for neutral amino acids: physiology and pathophysiology. Physiology (Bethesda) 2008; 23: 95-103.
163. Broer S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 2008; 88: 249-86.
164. Bermingham JR, Jr., Pennington J. Organization and expression of the SLC36 cluster of amino acid transporter genes. Mamm Genome 2004; 15: 114-25.
165. Boll M, Foltz M, Anderson CM, et al. Substrate recognition by the mammalian proton-dependent amino acid transporter PAT1. Mol Membr Biol 2003; 20: 261-9.
166. Boll M, Foltz M, Rubio-Aliaga I, Daniel H. A cluster of proton/amino acid transporter genes in the human and mouse genomes. Genomics 2003; 82: 47-56.
167. Broer S, Bailey CG, Kowalczuk S, et al. Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. J Clin Invest 2008; 118: 3881-92.
168. Geller J, Kronn D, Jayabose S, Sandoval C. Hereditary folate malabsorption: family report and review of the literature. Medicine (Baltimore) 2002; 81: 51-68.
169. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009; 11: e4.
170. Zhao R, Shin DS, Diop-Bove N, Ovits CG, Goldman ID. Random mutagenesis of the proton-coupled folate transporter (SLC46A1), clustering of mutations, and the bases for associated losses of function. J Biol Chem 2011; 286: 24150-8.
171. Shin DS, Mahadeo K, Min SH, et al. Identification of novel mutations in the proton-coupled folate transporter (PCFTSLC46A1) associated with hereditary folate malabsorption. Mol Genet Metab 2011; 103: 33-7.
172. Zhao R, Shin DS, Goldman ID. Vulnerability of the cysteine-less proton-coupled folate transporter (PCFT-SLC46A1) to mutational stress associated with the substituted cysteine accessibility method. Biochim Biophys Acta 2011; 1808: 1140-5.
173. Shin DS, Min SH, Russell L, Zhao R, Fiser A, Goldman ID. Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption. Blood 2010; 116: 5162-9.
174. Mahadeo K, Diop-Bove N, Shin D, et al. Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. Am J Physiol Cell Physiol 2010; 299: C1153-61.
175. Zhao R, Unal ES, Shin DS, Goldman ID. Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method. Biochemistry 2010; 49: 2925-31.
176. Li N, Singh P, Mandrell KM, Lai Y. Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters. Mol Pharm 2010; 7: 630-41.
177. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos 2012; 40: 1164-9.
178. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117: 333-45.